IE50984B1 - An orally administered drug form comprising a polar bioactive agent and an adjuvant - Google Patents

An orally administered drug form comprising a polar bioactive agent and an adjuvant

Info

Publication number
IE50984B1
IE50984B1 IE454/81A IE45481A IE50984B1 IE 50984 B1 IE50984 B1 IE 50984B1 IE 454/81 A IE454/81 A IE 454/81A IE 45481 A IE45481 A IE 45481A IE 50984 B1 IE50984 B1 IE 50984B1
Authority
IE
Ireland
Prior art keywords
acid
drug form
polar
form according
caffeine
Prior art date
Application number
IE454/81A
Other languages
English (en)
Other versions
IE810454L (en
Original Assignee
Interx Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interx Research Corp filed Critical Interx Research Corp
Publication of IE810454L publication Critical patent/IE810454L/xx
Publication of IE50984B1 publication Critical patent/IE50984B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IE454/81A 1980-03-07 1981-03-03 An orally administered drug form comprising a polar bioactive agent and an adjuvant IE50984B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12810180A 1980-03-07 1980-03-07

Publications (2)

Publication Number Publication Date
IE810454L IE810454L (en) 1981-09-07
IE50984B1 true IE50984B1 (en) 1986-09-03

Family

ID=22433643

Family Applications (1)

Application Number Title Priority Date Filing Date
IE454/81A IE50984B1 (en) 1980-03-07 1981-03-03 An orally administered drug form comprising a polar bioactive agent and an adjuvant

Country Status (14)

Country Link
US (1) US4462991A (enExample)
EP (1) EP0036145B1 (enExample)
JP (1) JPS56166849A (enExample)
AT (1) ATE13487T1 (enExample)
AU (1) AU556734B2 (enExample)
CA (1) CA1165689A (enExample)
DE (1) DE3170684D1 (enExample)
DK (1) DK102181A (enExample)
ES (1) ES8301632A1 (enExample)
GR (1) GR74442B (enExample)
IE (1) IE50984B1 (enExample)
NZ (1) NZ196349A (enExample)
PT (1) PT72576B (enExample)
ZA (1) ZA811515B (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU541247B2 (en) * 1979-12-20 1985-01-03 R.P. Scherer Corporation Adjuvants for rectal delivery of drug substances
GR75219B (enExample) * 1980-04-21 1984-07-13 Merck & Co Inc
JPS57188526A (en) * 1981-05-14 1982-11-19 Takeda Chem Ind Ltd Peptide-containing pharmaceutical preparation
SE8302689L (sv) * 1982-05-14 1983-11-15 Richter Gedeon Vegyeszet Farmaceutiska kompositioner innehallande flera aktiva bestandsdelar
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
JPS6061523A (ja) * 1983-09-16 1985-04-09 Shionogi & Co Ltd 経口用ドブタミン製剤
US4703042A (en) * 1984-05-21 1987-10-27 Bodor Nicholas S Orally active heparin salts containing multivalent cationic units
EP0177342A3 (en) * 1984-10-04 1987-12-02 Genentech, Inc. Oral formulation of therapeutic proteins
US4822773A (en) * 1985-06-28 1989-04-18 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4729989A (en) * 1985-06-28 1988-03-08 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4692441A (en) * 1985-08-16 1987-09-08 Merck & Co., Inc. Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
US5167947A (en) * 1989-10-26 1992-12-01 Southwest Research Institute Enhancement of absorption of radioprotective drugs
US6099856A (en) * 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US6344213B1 (en) 1996-03-29 2002-02-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5443841A (en) * 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US5578323A (en) * 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
US6916489B2 (en) 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US5811127A (en) * 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5401516A (en) * 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
JP4361601B2 (ja) * 1993-04-22 2009-11-11 エミスフェアー・テクノロジーズ・インク 経口薬剤移送組成物およびその方法
US20010003001A1 (en) * 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5965121A (en) * 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1151836C (zh) * 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5820881A (en) * 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
US5824345A (en) * 1995-06-07 1998-10-20 Emisphere Technologies, Inc. Fragrances and flavorants
US5667806A (en) * 1995-06-07 1997-09-16 Emisphere Technologies, Inc. Spray drying method and apparatus
US6051258A (en) * 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US6084112A (en) * 1995-09-11 2000-07-04 Emisphere Technologies, Inc. Method for preparing ω-aminoalkanoic acid derivatives from cycloalkanones
CA2258264A1 (en) 1996-06-14 1997-12-18 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
EP0886471A4 (en) 1996-11-18 2002-07-17 Emisphere Tech Inc METHODS AND COMPOSITIONS FOR INDUCING ORAL TOLERANCE IN MUZZLES
PA8444901A1 (es) * 1997-01-28 2000-05-24 Hoffmann La Roche Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios
US5804688A (en) * 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5990166A (en) * 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5876710A (en) * 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5879681A (en) * 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5939381A (en) * 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6060513A (en) * 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) * 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
US6197746B1 (en) 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
JP2002501616A (ja) 1997-05-19 2002-01-15 リプリゲン コーポレーション 自閉的症候群を鑑別診断および治療する際の助けとするための方法
ES2242412T3 (es) 1998-07-27 2005-11-01 Emisphere Technologies, Inc. Compuestos que permiten administrar agentes activos y composiciones a base de estos compuestos.
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
CN1313439C (zh) 1998-08-07 2007-05-02 艾米斯菲尔技术有限公司 用于送递活性剂的化合物和组合物
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2000040203A2 (en) 1999-01-08 2000-07-13 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agent compounds
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
AU3378100A (en) 1999-02-26 2000-09-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IL145546A0 (en) 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
WO2001044199A1 (en) * 1999-12-16 2001-06-21 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP4879433B2 (ja) 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
JP2004521857A (ja) 2000-06-29 2004-07-22 エミスフェアー・テクノロジーズ・インク 活性剤の送達のための化合物及び組成物
US20040109920A1 (en) * 2002-12-04 2004-06-10 Bioactives Llc Coated carotenoid cyclodextrin complexes
JP2005209106A (ja) * 2004-01-26 2005-08-04 Nec Corp 携帯通信端末、受信メール管理方法、プログラムおよび記録媒体
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
EP3544614A4 (en) 2016-11-28 2020-08-05 Lipocine Inc. TESTOSTERONE UNDECANOATE ORAL TREATMENT
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
EP4222502A1 (en) * 2020-09-29 2023-08-09 F. Hoffmann-La Roche AG A method for determining the level of vitamin d and metabolites thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE340744C (de) * 1916-08-04 1921-09-20 Knoll & Co Verfahren zur Darstellung neutral loeslicher Doppelverbindungen von Dialkylxanthinen sowie von ihren N-Acidylderivaten
GB905092A (en) * 1959-07-10 1962-09-05 American Cyanamid Co Improved tetracycline antibiotic compositions
US3159537A (en) * 1960-12-20 1964-12-01 American Cyanamid Co Potentiation of tetracycline by phosphinic acid
GB1285361A (en) * 1969-04-18 1972-08-16 Rech S Et D Applic Scient Et M Improvements in or relating to pyrazolidine derivatives
FR2124101A1 (en) * 1971-02-05 1972-09-22 Merck & Co Inc Sleep-inducing compns contng salicylamide - and glyceryl guaiacolate
FR2258171A1 (en) * 1974-01-21 1975-08-18 Aries Robert Oral male contraceptives - comprising steroidal progestogens potentiated with hydroxybenzoic acids
HU170329B (enExample) * 1974-12-12 1977-05-28
FR2379285A2 (fr) * 1977-02-08 1978-09-01 Expl Marques Brevets Et Nouvelle composition a base d'acide salicylique et de corticoide
JPS56122310A (en) * 1980-03-03 1981-09-25 Teijin Ltd Suppository

Also Published As

Publication number Publication date
ZA811515B (en) 1982-10-27
AU556734B2 (en) 1986-11-20
US4462991A (en) 1984-07-31
EP0036145B1 (en) 1985-05-29
NZ196349A (en) 1984-08-24
GR74442B (enExample) 1984-06-28
IE810454L (en) 1981-09-07
ES500186A0 (es) 1983-01-01
ES8301632A1 (es) 1983-01-01
ATE13487T1 (de) 1985-06-15
DK102181A (da) 1981-09-08
CA1165689A (en) 1984-04-17
EP0036145A1 (en) 1981-09-23
DE3170684D1 (en) 1985-07-04
AU6805781A (en) 1981-09-17
PT72576B (en) 1985-11-25
PT72576A (en) 1981-03-01
JPS56166849A (en) 1981-12-22

Similar Documents

Publication Publication Date Title
EP0036145B1 (en) An orally administered drug form comprising a polar bioactive agent and an adjuvant
US4834984A (en) Controlled release dihydrocodeine composition
US4309406A (en) Sustained release pharmaceutical compositions
CN104812378B (zh) 固体剂型
EP1416919A1 (en) Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
SK55896A3 (en) Pharmaceutical composition containing the ace inhibitor ramipril and a dihydropyridine compound
ES2680444T3 (es) Forma de dosificación oral sólida de irinotecán para el tratamiento del cáncer
EP1750677B1 (en) Oral therapeutic compound delivery system
JP3874793B2 (ja) イブプロフェンおよびコデイン含有の改良された医薬処方
US20100209511A1 (en) sustained release pharmaceutical formulation
EP3785698A1 (en) Edaravone pharmaceutical composition
CZ20002939A3 (cs) Farmaceutické kombinace obsahující tramadol
CA2728514C (en) Paediatric compositions for treating multiple sclerosis
JP2002534379A5 (enExample)
US20050272717A1 (en) Treatment of aromatase inhibitor therapy-related osteoporosis
RU99119233A (ru) Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени
EP2853257B1 (en) Pharmaceutical formulations of linagliptin
ES2267301T3 (es) Composicion bifasica con tramadol.
US20130338220A1 (en) Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
JP2665357B2 (ja) 心不全治療用医薬組成物
JP2001508769A (ja) アレンドロン酸塩及び胃排出を促進する薬剤を含有する医薬組成物
KR20170086053A (ko) 디메틸 푸마르산염을 포함하는 제약학적 매트릭스 제제
ES2774473T3 (es) Forma de dosificación combinada de un antagonista del receptor opioide mu y un agente opioide
US20040068000A1 (en) Compression coated tablets
JP2002518330A (ja) 処置方法

Legal Events

Date Code Title Description
MM4A Patent lapsed